Skip to content

Study · Animal study (in vivo) · mouse · 2021

1 result

Metabolic derangement in polycystic kidney disease mouse models is ameliorated by mitochondrial-targeted antioxidants.

Daneshgar N, Baguley AW, Liang PI, Wu F, Chu Y, Kinter MT, Benavides GA, Johnson MS, Darley-Usmar V, Zhang J, Chan KS, Dai DF

Communications biology20 Oct 2021Cited by 30 (Europe PMC)

PMID34671066 (opens in a new tab)PMCIDPMC8528863 (opens in a new tab)DOI10.1038/s42003-021-02730-w (opens in a new tab)PepBankPUB-34671066
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressively enlarging cysts. Here we elucidate the interplay between oxidative stress, mitochondrial dysfunction, and metabolic derangement using two mouse models of PKD1 mutation, PKD1RC/null and PKD1RC/RC. Mouse kidneys with PKD1 mutation have decreased mitochondrial complexes activity. Targeted proteomics analysis shows a significant decrease in proteins involved in the TCA cycle, fatty acid oxidation (FAO), respiratory complexes, and endogenous antioxidants. Overexpressing mitochondrial-targeted catalase (mCAT) using adeno-associated virus reduces mitochondrial ROS, oxidative damage, ameliorates the progression of PKD and partially restores expression of proteins involved in FAO and the TCA cycle. In human ADPKD cells, inducing mitochondrial ROS increased ERK1/2 phosphorylation and decreased AMPK phosphorylation, whereas the converse was observed with increased scavenging of ROS in the mitochondria. Treatment with the mitochondrial protective peptide, SS31, recapitulates the beneficial effects of mCAT, supporting its potential application as a novel therapeutic for ADPKD.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mouse models of polycystic kidney disease, treatment with SS31 recapitulated the beneficial effects of mitochondrial-targeted catalase.

    In plain wordsIn mouse models of polycystic kidney disease, SS31 treatment reproduced the benefits seen with a mitochondria-targeted catalase.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Direction not reportedBeneficial effects in PKD mouse models (similar to mCAT)
    Study

    mousen: not reported in source

    PKD1 RC/null and PKD1 RC/RC mouse models of ADPKD
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment with the mitochondrial protective peptide, SS31, recapitulates the beneficial effects of mCAT, supporting its potential application as a novel therapeutic for ADPKD.
    1 context sentence
    Summary · context
    Here we elucidate the interplay between oxidative stress, mitochondrial dysfunction, and metabolic derangement using two mouse models of PKD1 mutation, PKD1RC/null and PKD1RC/RC.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.